Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

I’m James Watson I’m working here as a post doc with Nick White in the clinical therapeutics unit, working on malaria mostly and drug pharmacokinetics. There are two types of malaria, falciparum and vivax. Falciparum is the better known one and it’s spread across Africa; there isn’t much vivax in Africa and it’s predominantly in Asia where it’s more than half the malaria, and it counts for maybe 15 million cases per year.

Malaria gives you a fever and the primary fever you treat exactly the same way for falciparum and vivax. However vivax has a characteristic of relapsing: you have these hidden parasites in your liver that come out and give you a new illness every three or four weeks. There’s only one drug that cleans your liver and stops this relapse which is primaquine. The problem with primaquine is that it causes anaemia in people with a genetic deficiency called G6PD deficiency. This is the most common deficiency in the world, so you can’t give primaquine to lots of people.

Primaquine destroys the older rather than the young red blood cells. We believe that it’s possible, by giving primaquine over a slightly longer duration - three weeks instead of two weeks - and starting with low doses and slowly escalating the dose over time, it’s possible to do something similar to control burning, where you start off and you burn a little bit. That stops dangerous anaemia in a patient and it gives the bone marrow time to respond and make new, younger red blood cells that are resistant to this toxic effect of primaquine.

The most important new research is a drug called tafenoquine developed by GSK. This is exactly the same as primaquine and it has the same toxic side effects, except that you can give it as one single dose. This is an important progress because you have to take primaquine over two weeks and lots of people don’t finished their treatment and therefore don’t cure themselves of these relapsing infections.

This research started off as a project trying to understand the dynamics of red blood cells and how this drug primaquine destroys red blood cells, and then we’ve transformed that into a new regimen that we could possibly give to G6PD deficient patients. In Asia, we think that there are millions of people who are G6PD deficient and who can’t take primaquine, so these people would directly benefit from a new regimen that would be safe. We have ethical approval to try this new regimen of primaquine in healthy volunteers. We’re starting this in the next few months, and this should hopefully enrol about 20 patients, and will be a proof of concept whether this idea works or not.

James Watson

James Watson analysis genetic and epidemiological data to characterize relapses in vivax malaria. He also develops statistical models to better understand the pharmacology of antimalarial drugs. James has a particular interest in G6PD deficiency in the context of radical curative drugs for vivax malaria, and works on developing a new primaquine regimen which would be safe in G6PD deficiency.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Lorenz von Seidlein: Malaria elimination in the Greater Mekong sub-region

Multidrug resistant P. falciparum malaria is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for artemisinin combination therapies, the main falciparum malaria medicines.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.